Literature DB >> 12773538

Evidence for distinct sodium-, dopamine-, and cocaine-dependent conformational changes in transmembrane segments 7 and 8 of the dopamine transporter.

Lene Norregaard1, Claus Juul Loland, Ulrik Gether.   

Abstract

Previously we obtained evidence based on engineering of Zn2+ binding sites that the extracellular parts of transmembrane segment 7 (TM7) and TM8 in the human dopamine transporter are important for transporter function. To further evaluate the role of this domain, we have employed the substituted cysteine accessibility method and performed 10 single cysteine substitutions at the extracellular ends of TM7 and TM8. The mutants were made in background mutants of the human dopamine transporter with either two (E2C) or five endogenous cysteines substituted (X5C) that render the transporter largely insensitive to cysteine modification. In two mutants (M371C and A399C), treatment with the sulfhydryl-reactive reagent [2-(trimethylammonium)-ethyl]methanethiosulfonate (MTSET) led to a substantial inhibition of [3H]dopamine uptake. In M371C this inactivation was enhanced by Na+ and blocked by dopamine. Inhibitors such as cocaine did not alter the effect of MTSET in M371C. The protection of M371C inactivation by dopamine required Na+. Because dopamine binding is believed to be Na+-independent, this suggests that dopamine induces a transport-associated conformational change that decreases the reactivity of M371C with MTSET. In contrast to M371C, cocaine decreased the reaction rate of A399C with MTSET, whereas dopamine had no effect. The protection by cocaine can either reflect that Ala-399 lines the cocaine binding crevice or that cocaine induces a conformational change that decreases the reactivity of A399C. The present findings add new functionality to the TM7/8 region by providing evidence for the occurrence of distinct Na+-, substrate-, and perhaps inhibitor-induced conformational changes critical for the proper function of the transporter.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773538     DOI: 10.1074/jbc.M303854200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Conformational flexibility of transmembrane helix VII of the human serotonin transporter impacts ion dependence and transport.

Authors:  Cody J Wenthur; Gustavo J Rodríguez; Charles P Kuntz; Eric L Barker
Journal:  Biochem Pharmacol       Date:  2010-07-15       Impact factor: 5.858

Review 2.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

3.  The role of cysteines and histidins of the norepinephrine transporter.

Authors:  Birger Wenge; Heinz Bönisch
Journal:  Neurochem Res       Date:  2013-03-23       Impact factor: 3.996

4.  Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia.

Authors:  Manju A Kurian; Juan Zhen; Shu-Yuan Cheng; Yan Li; Santosh R Mordekar; Philip Jardine; Neil V Morgan; Esther Meyer; Louise Tee; Shanaz Pasha; Evangeline Wassmer; Simon J R Heales; Paul Gissen; Maarten E A Reith; Eamonn R Maher
Journal:  J Clin Invest       Date:  2009-05-26       Impact factor: 14.808

5.  Infantile parkinsonism-dystonia: a dopamine "transportopathy".

Authors:  Craig Blackstone
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

6.  Antagonist-induced conformational changes in dopamine transporter extracellular loop two involve residues in a potential salt bridge.

Authors:  Jon D Gaffaney; Madhur Shetty; Bruce Felts; Akula-Bala Pramod; James D Foster; L Keith Henry; Roxanne A Vaughan
Journal:  Neurochem Int       Date:  2013-11-20       Impact factor: 3.921

7.  The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter.

Authors:  Jufang Shan; Jonathan A Javitch; Lei Shi; Harel Weinstein
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.